Pharmacogenomics Journal is categorized under Periodical Publishers in New York City, NY .
Pharmacogenomics Journal was established in 0, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Periodical Publishers business, which does work in the B2B market, and is classified as a Periodical Publishers, under code number 5111200 by the NAICS.
If you are seeking more information, feel free to contact David Bagshaw, Sales Executive at the company’s branch by writing to 75 Varick St Floor 9, New York City, New York NY 10013 or by phoning (212) 726-9200. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Pharmacogenomics Journal |
| Contact Person: | David Bagshaw, Sales Executive |
| Address: | 75 Varick St Floor 9, New York City, New York 10013 |
| Phone Number: | (212) 726-9200 |
| Website Address: | nature.com |
| Annual Revenue (USD): | $1.000.000 to $2.499.999 |
| Location Type: | Branch |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Periodical Publishers |
| SIC Code: | 2721 |
| NAICS Code: | 5111200 |
| Share This Business: |
Pharmacogenomics Journal was started in 0 to provide professional Periodical Publishers under the SIC code 2721 and NAICS code 5111200. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact David Bagshaw, Sales Executive for inquiries that concern Pharmacogenomics Journal by calling the company number (212) 726-9200, as your correspondence is most welcome. Additionally, the physical location of the branch of Pharmacogenomics Journal can be found at the coordinates 40.722663,-74.006406 as well as the street address 75 Varick St Floor 9 in New York City, New York 10013.
For its online presence, you may visit Pharmacogenomics Journal’s website at nature.com and engage with its social media outlets through on Twitter and on Facebook.